Twice-daily Vuity meets primary endpoint in phase 3 presbyopia trial

Twice-daily Vuity for presbyopia met its primary efficacy endpoint in the phase 3 VIRGO trial, according to a press release from Allergan/AbbVie.
Vuity (pilocarpine HCl ophthalmic solution 1.25%) improved near vision without compromising distance vision at hour 9, 3 hours after the second drop, on day 14 of the study, the release said.
“We know that many people with age-related blurry near vision are interested in the potential use of Vuity beyond once-daily administration to help manage their condition,” Michael R. Robinson, MD, vice president, global therapeutic area head,

Twice-daily Vuity for presbyopia met its primary efficacy endpoint in the phase 3 VIRGO trial, according to a press release from Allergan/AbbVie.
Vuity (pilocarpine HCl ophthalmic solution 1.25%) improved near vision without compromising distance vision at hour 9, 3 hours after the second drop, on day 14 of the study, the release said.
“We know that many people with age-related blurry near vision are interested in the potential use of Vuity beyond once-daily administration to help manage their condition,” Michael R. Robinson, MD, vice president, global therapeutic area head,